EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma

Linlin Qu, Yannan Liu, Jianjun Deng, Xiaoxuan Ma, Daidi Fan

Journal of Pharmaceutical Analysis · 2023-05 · 13 (5) · 463-482

DOI: 10.1016/j.jpha.2023.03.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2023-05. Verfasst von Linlin Qu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shaanxi Key Laboratory of Degradable Biomedical Materials, School of Chemical Engineering, Northwest University, Xi'an, 710069, China. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Key Research and Development Projects of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Ginsenoside Rk3, an important and rare saponin in heat-treated ginseng, is generated from Rg1 and has a smaller molecular weight. However, the anti-HCC efficacy and mechanisms of ginsenoside Rk3 have not yet been characterized. Here, we investigated the mechanism by which ginsenoside Rk3, a tetracyclic triterpenoid rare ginsenoside, inhibits the growth of HCC. We first explored the possible potential targets of Rk3 through network pharmacology. Both in vitro (HepG2 and HCC-LM3 cells) and in vivo (primary liver cancer mice and HCC-LM3 subcutaneous tumor-bearing mice) studies revealed that Rk3 significantly inhibits the proliferation of HCC. Meanwhile, Rk3 blocked the cell cycle in HCC at the G1 phase and induced autophagy and apoptosis in HCC. Further proteomics and siRNA experiments showed that Rk3 regulates the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway to inhibit HCC growth, which was validated by molecular docking and surface plasmon resonance. In conclusion, we report the discovery that ginsenoside Rk3 binds to PI3K/AKT and promotes autophagy and apoptosis in HCC. Our data strongly support the translation of ginsenoside Rk3 into novel PI3K/AKT-targeting therapeutics for HCC treatment with low toxic side effects.

Schlagwörter

Stichwörter der Autor:innen

ApoptosisAutophagyGinsenoside Rk3Hepatocellular carcinomaPI3K/AKT pathway

Autor:innen und Institutionen

  • Shaanxi Key Laboratory of Degradable Biomedical Materials, School of Chemical Engineering, Northwest University, Xi'an, 710069, China.
  • Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China.
  • Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China.
  • Xi'an Giant Biotechnology Co., Ltd., Xi'an, 710076, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Key Research and Development Projects of Shaanxi Province
  • Natural Science Basic Research Program of Shaanxi Province

Zitieren

APA

Qu, L., Liu, Y., Deng, J., Ma, X., & Fan, D. (2023). Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma. Journal of Pharmaceutical Analysis, 13(5), 463-482. https://doi.org/10.1016/j.jpha.2023.03.006

Vancouver

Qu L, Liu Y, Deng J, Ma X, Fan D. Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma. Journal of Pharmaceutical Analysis. 2023;13(5):463-482. doi:10.1016/j.jpha.2023.03.006

BibTeX
@article{Qu2023,
  author = {Qu, Linlin and Liu, Yannan and Deng, Jianjun and Ma, Xiaoxuan and Fan, Daidi},
  title = {Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2023},
  volume = {13},
  number = {5},
  pages = {463--482},
  doi = {10.1016/j.jpha.2023.03.006}
}
Kostenlos starten →